ATE236126T1 - Metalloproteinase inhibitoren - Google Patents

Metalloproteinase inhibitoren

Info

Publication number
ATE236126T1
ATE236126T1 AT97912351T AT97912351T ATE236126T1 AT E236126 T1 ATE236126 T1 AT E236126T1 AT 97912351 T AT97912351 T AT 97912351T AT 97912351 T AT97912351 T AT 97912351T AT E236126 T1 ATE236126 T1 AT E236126T1
Authority
AT
Austria
Prior art keywords
methoxysuccinamide
pyridin
isobutyl
propyl
hydroxy
Prior art date
Application number
AT97912351T
Other languages
English (en)
Inventor
Raymond Paul Beckett
Mark Whittaker
Andrew Miller
Fionna Mitchell Martin
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Application granted granted Critical
Publication of ATE236126T1 publication Critical patent/ATE236126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
AT97912351T 1997-11-13 1997-11-13 Metalloproteinase inhibitoren ATE236126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1997/003132 WO1999025693A1 (en) 1997-11-13 1997-11-13 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE236126T1 true ATE236126T1 (de) 2003-04-15

Family

ID=10807699

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97912351T ATE236126T1 (de) 1997-11-13 1997-11-13 Metalloproteinase inhibitoren

Country Status (21)

Country Link
EP (1) EP1030842B1 (de)
JP (1) JP2001523666A (de)
KR (1) KR100485479B1 (de)
AT (1) ATE236126T1 (de)
AU (1) AU740420B2 (de)
BR (1) BR9714934A (de)
CA (1) CA2310593C (de)
DE (1) DE69720554T2 (de)
DK (1) DK1030842T3 (de)
ES (1) ES2195122T3 (de)
GB (1) GB2333524A (de)
HU (1) HUP0002811A3 (de)
IL (1) IL135210A0 (de)
NO (1) NO315702B1 (de)
NZ (1) NZ503642A (de)
PL (1) PL189542B1 (de)
PT (1) PT1030842E (de)
RU (1) RU2198164C2 (de)
TR (1) TR200001353T2 (de)
TW (1) TW474919B (de)
WO (1) WO1999025693A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2144819T3 (es) * 1994-01-20 2000-06-16 British Biotech Pharm L-terc-leucina-2-piridilamida.
AU2986295A (en) * 1995-07-19 1997-02-18 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors

Also Published As

Publication number Publication date
HUP0002811A2 (hu) 2001-01-29
EP1030842A1 (de) 2000-08-30
PL189542B1 (pl) 2005-08-31
DE69720554T2 (de) 2004-01-08
TW474919B (en) 2002-02-01
NO315702B1 (no) 2003-10-13
DK1030842T3 (da) 2003-07-28
NO20002480L (no) 2000-05-12
HUP0002811A3 (en) 2002-11-28
ES2195122T3 (es) 2003-12-01
NO20002480D0 (no) 2000-05-12
TR200001353T2 (tr) 2000-10-23
EP1030842B1 (de) 2003-04-02
AU740420B2 (en) 2001-11-01
CA2310593A1 (en) 1999-05-27
PT1030842E (pt) 2003-07-31
PL340494A1 (en) 2001-02-12
NZ503642A (en) 2001-10-26
AU4958497A (en) 1999-06-07
JP2001523666A (ja) 2001-11-27
GB9816317D0 (en) 1998-09-23
IL135210A0 (en) 2001-05-20
BR9714934A (pt) 2000-10-03
KR20010031879A (ko) 2001-04-16
CA2310593C (en) 2007-05-08
KR100485479B1 (ko) 2005-04-27
DE69720554D1 (de) 2003-05-08
WO1999025693A1 (en) 1999-05-27
RU2198164C2 (ru) 2003-02-10
GB2333524A (en) 1999-07-28

Similar Documents

Publication Publication Date Title
ITMI921601A1 (it) Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
NZ501277A (en) -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
ATE297203T1 (de) Antithrombotische mitteln
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
ES2114931T3 (es) Nuevos esteres esteroidales.
DE69015736T2 (de) 7-Keto- und 7-Hydroxy-androsta-3,5-dien-3-carbonsäure Derivate.
ES2156120T3 (es) Derivados arilamidicos.
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
EP0627442A4 (de) Methode und vorrichtung zur reinigung oder kühlung von gas.
ES2059755T3 (es) Derivados organicos de hidrazina para uso farmaceutico.
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
DE69720554D1 (de) Metalloproteinase inhibitoren
Tandon et al. Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenol
DE60216239T8 (de) Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie
ITPD920145A1 (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
DK0398217T3 (da) Dehydrocholecalciferolderivater
EA200400096A1 (ru) Применение корриноидов при кожных заболеваниях
AU640647B2 (en) 3-butenamide derivatives
DE69414396T2 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
ES2170183T3 (es) Benzoilguanidinas sustituidas con 4-fluoroalquilo, procedimiento para su preparacion, su utilizacion como medicamento, asi como medicamento que las contiene.
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1030842

Country of ref document: EP

REN Ceased due to non-payment of the annual fee